|
KMID : 0648320100160040044
|
|
Journal of The Korean Society of Hypertension
2010 Volume.16 No. 4 p.44 ~ p.53
|
|
|
Telmisartan Versus Carvedilol in Hypertensive Patients with Metabolic Syndrome: Effects on Blood Pressure, Arterial Stiffness, Blood Glucose, and Lipid Metabolism
|
|
Kim Yong-Seok
Kim So-Yeon
Bae Jun-Ho
Na Deuk-Young
Rhee Moo-Yong
Lee Myoung-Mook
Huh Hee-Jin
Chae Seok-Lae
Kim Young-Kwon
|
|
|
Abstract
|
|
|
Background: We compared the effects of telmisartan and carvedilol on blood pressure (BP), aortic stiffness, glucose, and lipid metabolism in hypertensive patients with metabolic syndrome (MS).
Methods: A total of 26 untreated hypertensive patients with MS was randomly assigned into either telmisartan (N=13) or carvedilol (N=13) group and treated for a 24-week period. Systolic and diastolic BPs were measured every 4 weeks. Fasting plasma glucose (FG), total cholesterol (TC), triglyceride (TG), HDL-cholesterol (HDL), LDL-cholesterol (LDL), adiponectin, brachial-ankle pulse wave velocity (baPWV), and heartfemoral PWV (hfPWV) were measured at baseline and at weeks 12 and 24.
Results: Systolic and diastolic BPs, baPWV, hfPWV were significantly decreased in both groups and there were no significant differences in the changes of BP, baPWV, and hfPWV between the two groups during the treatment period. In telmisartan group, there were no significant changes in levels of FG, TC, TG, HDL, LDL, and adiponectin at week 24. In carvedilol group, there were no significant changes in levels of FG, TC, and LDL at week 24. However, TG level was significantly increased (baseline, 162.9±64.6 mg/dL; week 24, 198.0 ±69.8 mg/dL; p=0.046), and levels of HDL (baseline, 48.7±8.8 mg/dL; week 24, 42.9±7.2 mg/dL; p=0.044) and adiponectin (baseline, 7.0±4.1 g/mL; week 24 5.8±3.2 g/mL; p=0.003) were significantly decreased.
Conclusion: Telmisartan and carvedilol are comparable in reducing BP and aortic stiffness. However, compared with telmisartan, carvedilol may adversely affect adiponectin level and lipid metabolism without adverse impact on FG in hypertensive patients with MS.
|
|
|
KEYWORD
|
|
|
Telmisartan, Carvedilol, Hypertension, Metabolic Syndrome
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|